Argenx SE (ARGX) Gets Upgraded to Buy From Hold at Deutsche Bank

Argenx SE (NASDAQ:ARGX) is one of the most profitable biotech stocks to invest in now. On July 8, Deutsche Bank analyst Emmanuel Papadakis upgraded Argenx SE (NASDAQ:ARGX) to Buy from Hold with a EUR 550 price target.

Is argenx SE (ARGX) the Best Cancer Stock to Invest in for Long-Term Gain?

A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases.

Argenx SE reported that it generated global product net sales of $790 million in Q1 2025, inclusive of both VYVGART and VYVGART SC.

The company also exhibited strong underlying fundamentals across key patient and prescriber metrics, with 99% product net sales growth year-over-year compared to Q1 2024, along with a 7% product net sales growth from Q4 2024.

Argenx SE is a biotech company that develops treatments for severe autoimmune diseases. The company operates through four segments: the United States, Japan, EMEA, and China.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.